+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Investigation Report on China's Diclofenac Market, 2019-2023

  • ID: 4828515
  • Report
  • August 2019
  • Region: China
  • 30 Pages
  • China Research & Intelligence
1 of 5
The Sales Value of Diclofenac in China was About CNY 103 Million in 2017, Slightly Lower than that in 2016

FEATURED COMPANIES

  • Ciba-Geigy
  • Fujisawa
  • KlingePharma
  • SS Pharmaceutical
  • MORE

Rheumatoid arthritis is a common, frequently-occurring disease. According to the 2018 Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis, in 2018, a total of 5 million people in China had rheumatoid arthritis. As an autoimmune disease, rheumatoid arthritis not only leads to common symptoms of rheumatism such as synovitis and arthralgia but also causes problems with skin and eyes. Its complications also include lung diseases, cardiovascular and cerebrovascular diseases and malignant tumors. As the disease progresses, the incidence of complications will gradually increase, and the disability rate will also rise. When the disease lasts one to five years, the disability rate is lower than 20%; when it lasts for more than 15 years, the disability rate is higher than 60%.

Non-steroidal anti-inflammatory drugs (NSAIDs) such as Diclofenac can be used to alleviate the pain, swelling and stiffness caused by rheumatoid arthritis. The mechanism of Diclofenac action is to selectively cleave the action of cyclooxygenase in arachidonic acid metabolism series, block the synthesis of prostaglandin E2 (PGE2) and inhibit mutagenicity and the effect of pain. Diclofenac is a phenylacetic acid drug that has remarkable anti-rheumatic, anti-inflammatory, analgesic and antipyretic effects.

The indications for different dosage forms of Diclofenac are different. For example, Diclofenac tablets and injections are clinically used to treat rheumatic and rheumatoid arthritis, ankylosing spondylitis, osteoarthrosis, moderate pain such as postoperative and post-traumatic pain and acute musculoskeletal diseases, and fever caused by inflammations. Diclofenac eye drops are used to prevent miosis in and treat inflammations after cataract extraction, treat non-infectious eye inflammations caused or not caused by surgeries, prevent postoperative inflammatory reactions and the formation of cystoid macular edema, promote the formation of filtration blebs after glaucoma filtering surgeries, and treat allergic conjunctivitis.

Starting from the 1970s, Swiss company Ciba-Geigy, SS Pharmaceutical and Wakamoto Pharmaceutical Co., Ltd. successively developed and launched Diclofenac products. After years of clinical application, Diclofenac remains an important product of Novartis. In 1993, it was introduced to China as a non-selective NSAID commonly seen in clinical application. Diclofenac takes up a large share of China's NSAID market in the dosage forms of tablets, capsules, injections, externally used gels, compound preparations, etc. Oral Diclofenac accounts for a large proportion. Since Diclofenac is a generic drug, there are more than 100 Diclofenac manufacturers in China. Foreign brands Voltaren, Difene and Diclac take up 75% of the market while domestic brands only take up 25%.

According to the publishers market survey, the sales value of Diclofenac in China was about CNY 103 million in 2017, slightly lower than that in 2016. In 2017, Beijing Novartis Pharma Co., Ltd. ranked the first on China's Diclofenac market, with market share by sales value reaching 45.30% and market share by sales volume reaching 35.20%. The other major market players were Shenyang Xingqi Pharmaceutical Co., Ltd., Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., KlingePharma and Fujisawa.

It's expected that, with the increasing number of patients with rheumatoid arthritis and other indications for Diclofenac, China's Diclofenac market still has certain development potential.

Topics covered:

  • Incidence of rheumatoid arthritis in China
  • Supply of and demand for Diclofenac in China
  • Retail prices of Diclofenac in China
  • Major factors influencing China's Diclofenac market
  • Prospect of China's Diclofenac market from 2019 to 2023
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ciba-Geigy
  • Fujisawa
  • KlingePharma
  • SS Pharmaceutical
  • MORE

1 Relevant Concepts of Diclofenac
1.1 Indications for Diclofenac
1.2 Development of Diclofenac in China
1.3 Patents and Government Approval on Diclofenac in China

2 Sales of Diclofenac in China, 2013-2017
2.1 Sales Value of Diclofenac
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Diclofenac
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Diclofenac by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules
2.3.3 Gels
2.3.4 Sprays
2.3.5 Suppositories
2.3.6 Injections
2.3.7 Eye Drops
2.3.8 Patches
2.3.9 Ointments (Creams)

3 Analysis of Major Diclofenac Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Diclofenac Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Beijing Novartis Pharma Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Diclofenac by Beijing Novartis Pharma Co., Ltd. in China
3.3 Shenyang Xingqi Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Diclofenac by Shenyang Xingqi Pharmaceutical Co., Ltd. in China
3.4 Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd.
3.5 KlingePharma
3.6 Fujisawa

4 Prices of Diclofenac in China, 2017-2018
4.1 Beijing Novartis Pharma Co., Ltd. (Voltaren)
4.2 Shenyang Xingqi Pharmaceutical Co., Ltd. (Difei)
4.3 Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. (Laibixin)
4.4 KlingePharma
4.5 Fujisawa (Difene)

5 Prospect of China's Diclofenac Market, 2019-2023
5.1 Factors Influencing Development of China's Diclofenac Market
5.1.1 Favorable Factors
5.1.2 Unfavorable Factors
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

Charts

Chart: Patents on Diclofenac in China
Chart: Government Approval on Diclofenac in China
Chart: Sales of Diclofenac in China, 2013-2017
Chart: Sales Value of Diclofenac in Parts of China, 2013-2017
Chart: Sales Volume of Diclofenac in China, 2013-2017
Chart: Sales Volume of Diclofenac in Parts of China, 2013-2017
Chart: Sales Value of Diclofenac Tablets in China, 2013-2017
Chart: Sales Volume of Diclofenac Tablets in China, 2013-2017
Chart: Sales Value of Diclofenac Capsules in China, 2013-2017
Chart: Sales Value of Diclofenac Gels in China, 2013-2017
Chart: Sales Value of Diclofenac Sprays in China, 2013-2017
Chart: Sales Value of Diclofenac Suppositories in China, 2013-2017
Chart: Sales Value of Diclofenac Injections in China, 2013-2017
Chart: Sales Value of Diclofenac Eye Drops in China, 2013-2017
Chart: Sales Value of Diclofenac Patches in China, 2013-2017
Chart: Sales Value of Diclofenac Ointments (Creams) in China, 2013-2017
Chart: Market Share of Top 5 Diclofenac Manufacturers by Sales Value in China, 2013-2017
Chart: Sales Value of Diclofenac by Beijing Novartis Pharma Co., Ltd. in China, 2013-2017
Chart: Sales Value of Diclofenac by Shenyang Xingqi Pharmaceutical Co., Ltd. in China, 2013-2017
Chart: Sales Value of Diclofenac by Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. in China, 2013-2017
Chart: Sales Value of Diclofenac by KlingePharma in China, 2013-2017
Chart: Sales Value of Diclofenac by Fujisawa in China, 2013-2017
Chart: Prices of Diclofenac by Beijing Novartis Pharma Co., Ltd. in Parts of China, 2017
Chart: Prices of Diclofenac by Shenyang Xingqi Pharmaceutical Co., Ltd. in Parts of China, 2017
Chart: Prices of Diclofenac by Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. in Parts of China, 2017
Chart: Prices of Diclofenac by KlingePharma in Parts of China, 2017
Chart: Prices of Diclofenac by Fujisawa in Parts of China, 2017
Chart: Forecast on Sales Value of Diclofenac in China, 2019-2023

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Novartis Pharma Co., Ltd.
  • Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd.
  • Ciba-Geigy
  • Fujisawa
  • KlingePharma
  • Shenyang Xingqi Pharmaceutical Co., Ltd.
  • SS Pharmaceutical
  • Wakamoto Pharmaceutical Co., Ltd
Note: Product cover images may vary from those shown
5 of 5

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Adroll
adroll